iKang Healthcare Group, Inc. (NASDAQ:KANG) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

iKang Healthcare Group (NASDAQ:KANG) opened at 13.91 on Tuesday. iKang Healthcare Group has a 12-month low of $11.70 and a 12-month high of $19.20.

iKang Healthcare Group (NASDAQ:KANG) last released its earnings results on Thursday, June 22nd. The medical research company reported ($0.49) EPS for the quarter. The business had revenue of $60.16 million during the quarter. iKang Healthcare Group had a negative net margin of 2.58% and a negative return on equity of 3.19%. Equities research analysts anticipate that iKang Healthcare Group will post $0.65 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/ikang-healthcare-group-inc-nasdaqkang-rating-increased-to-hold-at-bidaskclub/1488961.html.

A number of institutional investors have recently added to or reduced their stakes in KANG. First Manhattan Co. raised its position in iKang Healthcare Group by 101.7% in the second quarter. First Manhattan Co. now owns 1,040,043 shares of the medical research company’s stock valued at $12,761,000 after buying an additional 524,318 shares during the last quarter. Athos Capital Ltd acquired a new position in iKang Healthcare Group during the second quarter valued at approximately $8,622,000. GLG Partners LP raised its position in iKang Healthcare Group by 15.5% in the second quarter. GLG Partners LP now owns 1,754,570 shares of the medical research company’s stock valued at $21,529,000 after buying an additional 235,056 shares during the last quarter. FIL Ltd raised its position in iKang Healthcare Group by 45.4% in the second quarter. FIL Ltd now owns 360,922 shares of the medical research company’s stock valued at $4,429,000 after buying an additional 112,615 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in iKang Healthcare Group by 14.6% in the second quarter. SG Americas Securities LLC now owns 44,608 shares of the medical research company’s stock valued at $547,000 after buying an additional 5,700 shares during the last quarter. Hedge funds and other institutional investors own 31.60% of the company’s stock.

About iKang Healthcare Group

iKang Healthcare Group, Inc provides preventive healthcare solutions, including a range of medical examinations services and value-added services, including disease screening, dental services and other services in China. The Company’s segments include medical examinations and other medical services, and dental services.

Receive News & Ratings for iKang Healthcare Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iKang Healthcare Group Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.